Independent variables | MDA at T6 | Time to SEC withdrawal | ||
Multivariable analysis | Multivariable analysis | |||
OR (95% CI) | P value | HR (95% CI) | P value | |
Male sex | 1.60 (1.05 to 2.45) | 0.028 | 0.68 (0.48 to 0.97) | 0.032 |
Age | 0.99 (0.98 to 1.02) | 0.892 | 1.01 (0.98 to 1.02) | 0.704 |
Smoking | 1.12 (0.70 to 1.80) | 0.626 | 1.15 (0.78 to 1.69) | 0.475 |
Psoriasis | 1.31 (0.83 to 2.06) | 0.240 | 1.07 (0.73 to 1.58) | 0.720 |
Bio-naïve | 0.93 (0.55 to 1.55) | 0.786 | 1.20 (0.78 to 1.86) | 0.397 |
Dosage SEC 300 mg | 1.67 (0.41 to 1.11) | 0.123 | 1.82 (0.36 to 0.84) | 0.006 |
BMI | 1.02 (0.97 to 1.06) | 0.461 | 1.04 (1.01 to 1.07) | 0.015 |
csDMARDs at T0 | 0.62 (0.41 to 0.95) | 0.030 | 1.87 (1.18 to 2.80) | 0.417 |
DAPSA at T0 | 0.94 (0.92 to 0.96) | 0.010 | 1.00 (0.98 to 1.01) | 0.638 |
P≤0.05.
The bold allows to highlight the values in which a statistical significance has been obtained.
Bio-naïve, first biological treatment line; BMI, body mass index; Coeff, coefficient; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAPSA, Disease Activity Index for Psoriatic Arthritis; MDA, minimal disease activity; SEC, secukinumab; T6, 6 months.